^
Association details:
| Biomarker: | HER-2 amplification + KRAS G12D |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HER2 mediates clinical resistance to the KRAS G12C inhibitor sotorasib, which is overcome by co-targeting SHP2
Published date:
10/26/2021
Excerpt:
A biopsy from progressing lung cancer of a patient treated with the KRASG12C inhibitor sotorasib was obtained, and the underlying resistance factors were analysed....We demonstrated acquisition of HER2 copy number gain and KRASG12C mutation retention in the post-progression biopsy....These findings establish HER2 copy number gain as a clinically relevant mechanism of resistance to pharmacological KRASG12C inhibition
DOI:
10.1016/j.ejca.2021.10.003
